A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

342

Enrollment

INDUSTRY

Sponsor class

Conditions

Lichen Planopilaris

Interventions

DRUG: Oral Brepocitinib
DRUG: Placebo

Sponsor

Priovant Therapeutics, Inc.